BD1063
BD1063 is a selective sigma receptor antagonist, with a reported binding affinity of Ki = 9 ± 1 nM for the sigma-1 receptor, and 702 ± 147 nM for the sigma-2 receptor. It has been shown to reduce the effects of methamphetamine in animal studies.
Pharmacology[edit | edit source]
BD1063 is a drug which acts as an antagonist for sigma receptors. It is selective for the sigma-1 subtype, and has less affinity for the sigma-2 subtype. Sigma receptors are a set of proteins located in the brain, which are thought to be involved in various drug effects and diseases, including schizophrenia, depression, and drug addiction.
Effects[edit | edit source]
BD1063 has been shown to reduce the self-administration of methamphetamine in rats, suggesting that it may have potential for use in the treatment of methamphetamine addiction. It has also been shown to produce antidepressant-like effects in animal studies, suggesting potential applications in the treatment of depression.
See also[edit | edit source]
References[edit | edit source]
BD1063 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD